Novartis AG (NVS)
163.09
+0.63
(+0.39%)
USD |
NYSE |
Sep 03, 16:00
160.40
-2.69
(-1.65%)
Pre-Market: 05:45
Novartis Cash from Investing (Quarterly) : -3.090B for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.090B |
| March 31, 2026 | -11.78B |
| December 31, 2025 | -2.111B |
| September 30, 2025 | -858.23M |
| June 30, 2025 | -2.263B |
| March 31, 2025 | 330.00M |
| December 31, 2024 | -3.033B |
| September 30, 2024 | -374.00M |
| June 30, 2024 | -3.207B |
| March 31, 2024 | -899.00M |
| December 31, 2023 | -1.112B |
| September 30, 2023 | -2.86B |
| June 30, 2023 | -1.068B |
| March 31, 2023 | 10.65B |
| December 31, 2022 | -1.466B |
| September 30, 2022 | 5.200B |
| June 30, 2022 | -11.63B |
| March 31, 2022 | 9.365B |
| December 31, 2021 | 4.563B |
| September 30, 2021 | -1.232B |
| June 30, 2021 | 97.00M |
| March 31, 2021 | 780.00M |
| December 31, 2020 | -649.68M |
| September 30, 2020 | -2.045B |
| June 30, 2020 | -425.00M |
| Date | Value |
|---|---|
| March 31, 2020 | -10.14B |
| December 31, 2019 | 318.00M |
| September 30, 2019 | -3.398B |
| June 30, 2019 | 25.00M |
| March 31, 2019 | 829.00M |
| December 31, 2018 | -4.945B |
| September 30, 2018 | -889.39M |
| June 30, 2018 | 4.344B |
| March 31, 2018 | -4.113B |
| December 31, 2017 | -1.025B |
| September 30, 2017 | -685.00M |
| June 30, 2017 | -337.00M |
| March 31, 2017 | -1.101B |
| December 31, 2016 | -1.073B |
| September 30, 2016 | -752.00M |
| June 30, 2016 | -844.00M |
| March 31, 2016 | -772.00M |
| December 31, 2015 | -1.69B |
| September 30, 2015 | -753.00M |
| June 30, 2015 | -1.784B |
| March 31, 2015 | -6.557B |
| December 31, 2014 | -919.00M |
| September 30, 2014 | 24.53M |
| June 30, 2014 | -1.120B |
| March 31, 2014 | 2.896B |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | -1.856B |
| Johnson & Johnson | -1.11B |
| Eli Lilly & Co. | -15.40B |
| Merck & Co., Inc. | -5.602B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 5.888B |
| Cash from Financing (Quarterly) | -2.031B |
| Free Cash Flow | 14.99B |
| Free Cash Flow Per Share (Quarterly) | 2.680 |
| Free Cash Flow to Equity (Quarterly) | 3.114B |
| Free Cash Flow to Firm (Quarterly) | 5.483B |
| Free Cash Flow Yield | 4.78% |